Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab plus trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR-trial

被引：4
|
作者：
Gluz, Oleg [1 ,2 ,3 ]
Kolberg-Liedtke, Cornelia [4 ]
Biehl, Claudia [5 ]
Christgen, Matthias [6 ]
Kuemmel, Sherko [7 ]
Grischke, Eva -Maria [8 ]
Augustin, Doris [9 ]
Braun, Michael [10 ]
Potenberg, Jochem [11 ]
Graeser, Monika
Kates, Ronald
Wuerstlein, Rachel [12 ,13 ]
Feuerhake, Friedrich [14 ]
Nitz, Ulrike [1 ,2 ]
Kreipe, Hans
Harbeck, Nadia [12 ,13 ]
机构：
[1] West German Study Grp, Monchengladbach, Germany
[2] Breast Ctr Niederrhein Johanniter Clin, Monchengladbach, Germany
[3] Univ Clin Cologne, Monchengladbach, Germany
[4] Charite Univ Med Berlin, Campus Mitte, Berlin, Germany
[5] City Hosp Dortmund, Westphalian Breast Ctr, Dortmund, Germany
[6] Med Sch Hannover, Inst Pathol, Hannover, Germany
[7] Breast Ctr, Clin Essen Mitte, Essen, Germany
[8] Womens Clin, Univ Clin Tuebingen, Tubingen, Germany
[9] Breast Ctr Ostbayern, DONAUISAR Clin Deggendorf, Deggendorf, Germany
[10] Rotkreuzklinikum Munich, Breast Ctr, Munich, Germany
[11] Evangel Waldkrankenhaus, Dept Oncol, Berlin, Germany
[12] Univ Munich LMU, Breast Ctr, Munich, Germany
[13] CCCLMU, Munich, Germany
[14] Med Sch Hannover, Inst Pathol, Monchengladbach, Germany
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P4-10-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-10-05
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer The Neoadjuvant WSG-TP-II Randomized Clinical Trial
    Gluz, Oleg
    Nitz, Ulrike A.
    Christgen, Matthias
    Kuemmel, Sherko
    Holtschmidt, Johannes
    Schumacher, Johannes
    Hartkopf, Andreas
    Potenberg, Jochem
    Lueedtke-Heckenkamp, Kerstin
    Just, Marianne
    Schem, Christian
    von Schumann, Raquel
    Kolberg-Liedtke, Cornelia
    Eulenburg, Christine Zu
    Schinkoethe, Timo
    Graeser, Monika
    Wuerstlein, Rachel
    Kates, Ronald E.
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JAMA ONCOLOGY, 2023, 9 (07) : 946 - 954
  • [22] Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
    Raphael, Jacques
    Gong, Inna Y.
    Nofech-Mozes, Sharon
    Bartlett, John M. S.
    Nafisi, Houman
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Pathological response and predictive role of tumour- infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial
    Liu, Zhenzhen
    Wang, Chengzheng
    Chen, Xiuchun
    Zhu, Jiujun
    Sun, Xianfu
    Xia, Qingxin
    Lu, Zhenduo
    Qiao, Jianghua
    Zhou, Yong
    Wang, Haixue
    Wang, Yi
    Yan, Min
    EUROPEAN JOURNAL OF CANCER, 2022, 165 : 157 - 168
  • [24] Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP): Single center experience
    Ha, J.
    Kim, J. E.
    Jeong, J. H.
    Ahn, J-H.
    Jung, K. H.
    Lee, H. J.
    Gong, G.
    Chae, E. Y.
    Kim, H. H.
    Chung, I. Y.
    Ko, B. S.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2018, 29 : 10 - 10
  • [25] De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel (vol 28, pg 2768, 2017)
    Nitz, U. A. D.
    Gluz, O.
    Christgen, M.
    Grischke, E. -M.
    Augustin, D.
    Kuemmel, S.
    Braun, M.
    Potenberg, J.
    Kohls, A.
    Krauss, K.
    Stefek, A.
    Schumacher, C.
    Forstbauer, H.
    Reimer, T.
    Fischer, H.
    Liedtke, C.
    Wuerstlein, R.
    Schumacher, J.
    Kates, R.
    Kreipe, H.
    Harbeck, N.
    WSG-ADAPT Investigators
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 355 - 355
  • [26] De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.
    Guarneri, Valentina
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Frassoldati, Antonio
    Bianchi, Giulia Valeria
    De Salvo, Gian Luca
    Orvieto, Enrico
    Curtarello, Matteo
    Pascual, Tomais
    Pare, Laia
    Ambroggi, Massimo
    Giorgi, Carlo Alberto
    Moretti, Gabriella
    Griguolo, Gaia
    Vicini, Roberto
    Prat, Aleix
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Efficacy and safety of neoadjuvant pertuzumab biosimilar TQB2440, trastuzumab and docetaxel in HR negative, HER2 positive breast cancer: a single-arm trial
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Xu, Dongdong
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
    M. V. Dieci
    A. Frassoldati
    D. Generali
    G. Bisagni
    F. Piacentini
    L. Cavanna
    K. Cagossi
    F. Puglisi
    A. Michelotti
    R. Berardi
    G. Banna
    A. Goubar
    G. Ficarra
    G. Griguolo
    Pierfranco Conte
    V. Guarneri
    Breast Cancer Research and Treatment, 2017, 163 : 295 - 302
  • [29] Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer
    Harbeck, N.
    Gluz, O.
    Christgen, M.
    Braun, M.
    Kuemmel, S.
    Schumacher, C.
    Potenberg, J.
    Kraemer, S.
    Kleine-Tebbe, A.
    Augustin, D.
    Aktas, B.
    Forstbauer, H.
    Tio, J.
    Liedtke, C.
    Kates, R. E.
    Wuerstlein, R.
    de Haas, S. L.
    Kiermaier, A.
    Kreipe, H. H.
    Nitz, U.
    CANCER RESEARCH, 2016, 76
  • [30] Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel plus trastuzumab plus lapat in HER2-positive early breast cancer.
    Eichler, Christian
    Gluz, Oleg
    Nitz, Ulrike
    Christgen, Matthias
    Krabisch, Petra
    Hackenberg, Reinhard
    Skrobol, Markus
    Mobus, Volker
    Kates, Ronald
    Schumacher, Johannes
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    Warm, Mathias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345